Nature Reviews Cancer contents April 2016 Volume 16 Number 4 pp197-270

If you are unable to see the message below, click here to view.

Advertisement
Apply precision medicine to advance your clinical trial outcomes  Power your precision medicine clinical trials with  genomic solutions  Download our complimentary precision medicine  white paper now
TABLE OF CONTENTS
April 2016 Volume 16 Number 4		Advertisement
Impact Factor 37.4 *	In this issue Research Highlights Reviews Analysis Perspectives Also this month  Featured article: Targeting metastasis Patricia S. Steeg	What can you measure with Flow Cytometry? Download our new white paper highlighting the power of Flow Cytometry in preclinical development and how to use these techniques to yield promising therapeutic candidates. Visit FlowMetric at AACR2016, Booth #2741. Download this Paper Now
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BEATSON INTERNATIONAL CANCER CONFERENCE Modelling the Mechanisms of Malignancy - In Vivo Veritas 3 July - 6 July 2016 - Glasgow, Scotland The conference will focus on the latest developments in the generation of animal models of cancer, with particular emphasis on how diverse aspects of the human disease may be faithfully recapitulated in the laboratory. Register here
Advertisement
Nature Insight Frontiers in Biology  This year's Frontiers in Biology Insight features Reviews on the processes that underlie metastasis, the positive influence of inflammation on tissue repair, the role of endothelial cells in organ development, growth and regeneration, the endoplasmic reticulum stress response and its contribution to disease, and antibiotic resistance.
Advertisement
ESO, CNIO and NRCO Conference on FAMILIAL CANCER Presented by: European School of Oncology | Centro Nacional de Investigaciones Oncológicas | Nature Reviews Clinical Oncology May 19-20, 2016 | Madrid, Spain REGISTER NOW!
RESEARCH HIGHLIGHTS Top Genetics: Common co-deletion isn't a silent passenger p197 | doi:10.1038/nrc.2016.26 Two studies in Science report that co-deletion of MTAP — which is common in CDKN2A-deleted cancers — is not a silent passenger event but renders cells sensitive to inhibition of protein arginine methyltransferase 5 (PRMT5), a dependency that could be therapeutically targeted in MTAP-deleted cancers. PDF Tumour metabolism: Feeding the TCA cycle in vivo p198 | doi:10.1038/nrc.2016.29 Two papers assess the role of glucose in lung cancer metabolism in vivo. PDF Chemotherapy: Preventing competitive release p199 | doi:10.1038/nrc.2016.28 Enriquez-Navas et al. show that an evolution-based adaptive treatment strategy is more effective than standard therapy for controlling tumour growth in orthotopic xenograft mouse models of breast cancer. PDF IN BRIEF Metastasis: The tumour microenvironment drives metastasis | Tumour suppression: To EMT or not to EMT? | Exercise: Running mobilizes tumour cell killers | Genetics: Pushing boundaries PDF Cancer JOBS of the week Postdoctoral Fellowship in Biomedical Science (Cancer Research) Institute for Cancer Genetics Columbia University Medical Center Epigenetic Regulation Of Cell Fate, Cancer And Metabolism University Medical Center Freiburg Postdoctoral Scientist – Cancer Biology University of Pittsburgh Head of Research, Belfer Center for Applied Cancer Science Dana-Farber Cancer Institute (DFCI) Postdoc Position for Molecular Cancer Biology University of Pittsburgh Cancer Institute (UPCI) More Science jobs from Cancer EVENT The 16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16) 12.09.16 Winchester, UK More science events from
Advertisement
AACR Precision Medicine Series Targeting the Vulnerabilities of Cancer Join us May 16-19, 2016 in Miami, FL to learn about cancer vulnerabilities, targeting the differences between cancer cells and normal cells, and the progress made in the discovery of new cancer therapeutics. Learn more.
REVIEWS		Top
Targeting metastasis Patricia S. Steeg p201 | doi:10.1038/nrc.2016.25 Tumour metastasis is a major contributor to the mortality of cancer patients, so why is this phase of cancer pathogenesis not routinely targeted? This Review discusses the possible strategies — including preclinical research, combination therapies and clinical trial designs — that could be developed to target metastasis. Abstract | Full Text | PDF
Vaccines for established cancer: overcoming the challenges posed by immune evasion Sjoerd H. van der Burg, Ramon Arens, Ferry Ossendorp, Thorbald van Hall & Cornelis J. M. Melief p219 | doi:10.1038/nrc.2016.16 This Review summarizes immune evasion mechanisms that limit the therapeutic efficacy of cancer vaccines. The authors discuss how improving vaccine design and using vaccines in combination with other anticancer therapies can boost treatment efficacy in patients with established cancers. Abstract | Full Text | PDF | Supplementary information
Radiation oncology in the era of precision medicine Michael Baumann, Mechthild Krause, Jens Overgaard, Jürgen Debus, Søren M. Bentzen, Juliane Daartz, Christian Richter, Daniel Zips & Thomas Bortfeld p234 | doi:10.1038/nrc.2016.18 This Review discusses technological and biologically based advances in radiotherapy. The authors envisage that these two major strategies will act synergistically to further widen the therapeutic window of radiation oncology in the era of precision medicine. Abstract | Full Text | PDF
ANALYSIS		Top
The importance of p53 pathway genetics in inherited and somatic cancer genomes Giovanni Stracquadanio, Xuting Wang, Marsha D. Wallace, Anna M. Grawenda, Ping Zhang, Juliet Hewitt, Jorge Zeron-Medina, Francesc Castro-Giner, Ian P. Tomlinson, Colin R. Goding, Kamil J. Cygan, William G. Fairbrother, Laurent F. Thomas, Pål Sætrom, Federica Gemignani, Stefano Landi, Benjamin Schuster-Böckler, Douglas A. Bell & Gareth L. Bond p251 | doi:10.1038/nrc.2016.15 Using genomic data, this Analysis demonstrates that commonly inherited single nucleotide polymorphisms (SNPs) occurring in genes of the p53 pathway affect the incidence of a broad range of cancers, more so than SNPs in other pathways. This has implications for p53-mediated tumour suppression in humans. Abstract | Full Text | PDF | Supplementary information
Advertisement
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions – explore the benefits of submitting your next manuscript to the journal.
PERSPECTIVES		Top
OPINION Inducing stable reversion to achieve cancer control Scott Powers & Robert E. Pollack p266 | doi:10.1038/nrc.2016.12 Current cancer therapies exert selective pressures that drive the evolution of drug-resistant clones. In this Opinion article, the authors argue that induction of stable tumour reversion represents an alternative strategy that could reduce resistance and thus effectively and durably treat cancer. Abstract | Full Text | PDF
Advertisement
ATTENDING AACR? MURPHY'S LAB WILL BE THERE! Everyone gets frustrated in the workplace, and we want to hear your gripes. Tell us what bothers you, and it might be featured in our next illustration. Stop by booth #2012 to pick up FREE Murphy's Lab merchandise. Date: Sunday, 17th April, 2016 Time: 1pm until supplies last Location: Nature booth #2012 LEARN MORE
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2014 Journal Citation Report (Thomson Reuters, 2015)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.